Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required)
National Institute of Allergy and Infectious Diseases (NIAID) · NIH Institute/Center · RFA-AI-27-002
Source: Grants.gov · View original posting ↗
- AwardWhat a single award can be worth — the funder's published per-award amount or floor–ceiling range.
- $10M total
- DeadlineFinal application due date.
- Nov 10, 2026
- Letter of intentDue date for the letter of intent (a short pre-application some funders require or request before the full proposal).
- —
- MechanismNIH activity code — the grant type (R01 research project, R21 exploratory, K series career development, F series fellowship, …).
- UM1
- DurationMaximum project period for a single award.
- —
- Expected awardsHow many awards the funder anticipates making under this opportunity.
- —
- Funding cycleHow often the program accepts applications (annual, multiple cycles per year, rolling, or one-time).
- One-time
- Open dateWhen applications open (or opened).
- Sep 1, 2026
- Total fundingThe overall pool the funder expects to commit across ALL awards under this opportunity — not what one project receives.
- $10M total
- Clinical trialWhether proposed projects must, may, or must not include a clinical trial.
- Required
Research areas
Auto-classified from the title and description (keyword-based) — may be imperfect.
Description
The purpose of this notice of funding opportunity (NOFO) is to solicit applications for an Infectious Diseases Clinical Trials Network (IDCTN). The IDCTN, comprised of the Clinical Trial Evaluation Units (CTEUs) and a Network Coordination Center (NCC), supports the evaluation of interventions for emerging and chronic infections. The CTEUs design and implement clinical trials and studies, while the NCC provides the administrative and operational framework for a collaborative, integrated network and engages with experts in the field to solicit and generate clinical trial concepts. The NCC and CTEUs will collaboratively create opportunities to advance investigators early in their careers and those new to the field.